1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This notice of funding opportunity (NOFO) promotes collaborative research programs to support the development/enhancement of infrastructure (e.g., tools, surveys, biospecimens, data) for Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) neuroscience research in low- and middle-income countries (LMICs) in Africa. Specifically, the National Institute on Aging (NIA) seeks to support Phase Innovation Awards Cooperative Agreement (UG3/UH3) projects to enable: (1) the formation of transformative collaborations between institutions/scientists in the US and LMICs in Africa; (2) the development, or enhancement of research infrastructure and resources for studies of AD/ADRD neuroscience relevant to Africaas well as to examine how social or behavioral factors influence AD/ADRD in Africa; (3) the initiation of pilot or exploratory studies that will inform future research for AD/ADRD neuroscience in Africa. These research infrastructure programs are expected to contribute to the long-term goals of building sustainable AD/ADRD neuroscience research capacity and research,ultimately leading to prevention and mitigation strategies for AD/ADRD in Africa. Income categories for LMICs in Africa are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
Funding Opportunity Number: RFA-AG-24-027. Assistance Listing: 93.866. Funding Instrument: CA. Category: HL.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Confirm the full requirements in the official notice before applying.
The published deadline was February 14, 2024, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in Alaska and Hawaii. Check the official notice for exact location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
After a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleNIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article